Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-α?

Atherosclerosis

Volumn 143, Issue 1, 1999, Pages 81-90

  Cigolini, M ^a   Tonoli, M ^a   Borgato, L ^a   Frigotto, L ^a   Manzato, F ^a   Zeminian, S ^a   Cardinale, C ^a   Camin, M ^a   Chiaramonte, E ^a   De Sandre, G ^a   Lunardi, C ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Adipose tissue; Fibrinolysis; Obesity; PAI 1; TNF

Indexed keywords

GENISTEIN; MESSENGER RNA; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCLONAL ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNDROME X; THROMBOEMBOLISM;

ADIPOSE TISSUE; BLOTTING, NORTHERN; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENISTEIN; HUMANS; OBESITY; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033028415     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00281-0     Document Type: Article

References (41)

1. Wiman B., Hamsten A. The fibrinolytic enzyme and its role in the etiology of thrombo-embolic disease. J. Biol. Chem. 259:1984;3644.
2. Colucci M., Paramo J.A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J. Clin. Invest. 75:1985;818.
3. Kruithof E.K.O., Tran-Thang C., Gudinchet A., Hauert J., Nicoloso G., Genton C., Welti H., Bachmann F.W. Fibrinolysis in pregnancy. A study of plasminogen activator inhibitors. Blood. 69:1987;460.
4. Wiman B., Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thrombotic disease. Semin. Thromb. Haemost. 26:1990;207.
5. Juhan-Vague I., Moerman B., De Cock F., Aillaud M.F., Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res. 33:1984;523.
6. Hamsten A., Wiman B., Faire U.D., Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313:1985;1557.
7. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 4:1987;3.
8. Sundell I.B., Nilsson T.K., Hallmans G., Hellsten G., Dahlen G.H. Interrelationship between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a) and established cardiovascular risk factors in a North Swedish population. Atherosclerosis. 80:1989;9.
9. Dawson S., Henney A. The status of PAI-1 as risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 95:1992;105.
10. Carmeliet P., Moons L., Dewerchin M., Mackman N., Breier G., Ploplis V., Muller M., Nagy A., Plow E., Gerard R., Edgington T., Risau W., Collen D. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann. N.Y. Acad. Sci. 811:1997;191.
11. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F. Inhibitory role of plasminogen activator-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180.
12. Farrehi P.M., Ozaki C.K., Carmeliet P., Fay W.P. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 10:1998;1002.
13. Björntorp P. Abdominal fat distribution and disease: an overview of epidemiological data. Ann. Med. 24:1992;15.
14. De Fronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173.
15. Cigolini M., Seidell J.C., Targher G., Deslypere J.P., Ellsinger B.M., Charzewska J., Cruz A., Björntorp P. Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: the European fat distribution study. Metabolism. 44:1995;35.
16. Landin K., Stigendal L., Krotkiewski M., Risberg B., Tengborn L., Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 39:1990;1044.
17. Juhan-Vague I., Alessi M.C., Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 42:1991;1.
18. Cigolini M., Targher G., Seidell J.C., Schiavon R., Manara F., Zenti M.G., Mattioli C., De Sandre G. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 106:1994;139.
19. Cigolini M., Targher G., Bergamo Andreis I.A., Tonoli M., Agostino G., De Sandre G. Visceral fat accumulation and its relation to plasma haemostatic factors in healthy men. Arterioscler. Thromb. Vasc. Biol. 16:1996;368.
20. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., Yamashita S., Miura M., Fukuda Y., Takemura K., Tokunaga K., Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2:1996;800.
21. Sawdey M., Loskutoff D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β J. Clin. Invest. 88:1991;1346.
22. Samad F., Yamamoto K., Loskutoff D. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J. Clin. Invest. 97:1996;37.
23. Lundgren C.H., Brown S.L., Nordt T.K., Sobel B.E., Fujii S. Elaboration of Type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation. 93:1996;106.
24. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes. 46:1997;860.
25. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87.
26. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95:1995;2111.
27. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409.
28. Hofmann C., Lorenz K., Braithwaite S.S., Colca J.R., Palazuk B.J., Hotamisligil G.S., Spiegelman B.M. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264.
29. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science. 271:1996;665.
30. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271.
31. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 389:1997;610.
32. Kolaczynski J.W., Morales L.M., Moore J.H. Jr., Considine R.V., Pietrzkowski Z., Noto P.F., Colberg J., Caro J.F. A new technique for biopsy of human abdominal fat under local anaesthesia with Lidocaine. Int. J. Obes. 18:1994;161.
33. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20 (1997) 1183.
34. Cigolini M., Smith U. Human adipose tissue in culture. VIII. Studies on insulin antagonistic effect of glucocorticoids. Metabolism. 28:1979;502.
35. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294.
36. Neuner P., Klosner G., Schauer E., Pourmojib M., Macheiner W., Grünwald C., Knobler R., Schwarz A., Luger T.A., Schwarz T. Pentoxifylline in vivo down regulates the release of IL-β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology. 83:1994;262.
37. Lauterbach R., Zembala M. Pentoxifylline reduces plasma tumor necrosis factor-alpha concentration in premature infants with sepsis. Eur.J. Pediatr. 155:1996;404.
38. Schmidt-Choudhury A., Furuta G.T., Lavigne J.A., Galli S.J., Wershill B.K. The regulation of tumor necrosis-alpha production in murine mast cells: pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-alpha by distinct mechanisms. Cell. Immunol. 171:1996;140.
39. van Hinsbergh V.W., Kooistra T., van den Berg E.A., Princen H.M., Fiers W., Emeis J.J. Tumor Necrosis Factor increases the production of Plasminogen Activator Inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 72:1988;1467.
40. Samad F., Yamamoto K., Pandey M., Loskutoff D.J. Elevated expression of transforming growth factor-β in adipose tissue from obese mice: a potential role in the obesity-linked increase in plasminogen activator inhibitor 1? Mol. Med. 3:1997;37.
41. van Hinsbergh V.W.M., Vermeer M., Koolwijk P., Grimbergen J., Kooistra T. Genistein reduces tumor necrosis factor-α induced plasminogen activator Inhibitor-1 transcription but not Urokinase expression in human endothelial cells. Blood. 84:1994;2984.